摘要
目的探讨不同分子分型乳腺浸润性导管癌手术病例标本中P53、表皮生长因子受体(EGFR)和Ki-67的表达及临床意义。方法采用免疫组织化学链霉菌抗生物素蛋白-过氧化物酶连接法法对2010年1月-2011年7月446例乳腺浸润性导管癌患者标本进行分子分型,并同时检测其P53、EGFR、Ki-67等的表达。结果 P53和Ki-67在人类表皮生长因子受体2(HER2)过表达型、基底细胞样型、未分类型中的表达明显强于管腔A型及管腔B型(P<0.05);HER2过表达型和未分类型中的EGFR表达明显强于管腔A型及管腔B型(P<0.05)。结论在使用雌激素受体、c-erbB-2等指标对浸润性导管癌进行分子分型时同时检测P53、EGFR及Ki-67等标记物,有助于更加精准的评估肿瘤的生物学行为及预后,对靶向药物的个体化治疗提供参考和疗效预测有重要意义。
Objective To investigate the expression and clinical significance of P53,epidermal growth factor receptor（EGFR） and Ki-67 in 446 cases of different kinds of breast infiltrative ductal cancer.Methods Immunohistochemistry streptavidin-perosidase method was used to categorize molecular types of 446 cases of breast infiltrative ductal cancer,as well as detect the expression of P53,EGFR and Ki-67 in these cancers.Results The positive expression of the P53 and Ki-67 in human epidermal growth factor receptor 2（HER2） positive,basal-like and unclassified types was significantly higher than that in luminal A and luminal B types（P〈0.05）.The positive expression of EGFR in HER2 positive,and unclassied types was significantly higher than that in luminal A and luminal B types（P〈0.05）.Conclusion The detection of P53,EGFR and Ki-67 markers in breast infiltrative ductal cancer through estrogen receptor or c-erbB-2 is helpful in accurately evaluating the biological behavior of breast cancer and its prognosis,which has a significant importance in providing individual treatment and predicting the clinical outcomes.
出处
《华西医学》
CAS
2012年第9期1349-1353,共5页
West China Medical Journal
